Your session is about to expire
← Back to Search
Nivolumab + Chemotherapy for Non-Hodgkin's Lymphoma
Study Summary
This trial is studying nivolumab in combination with DA-REPOCH to treat patients with aggressive B-cell non-Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have hepatitis C with cirrhosis.My kidney function, measured by creatinine or GFR, is within the required range.I am a woman who can have children and my pregnancy test was negative.I am a man and will use effective birth control during and 3 months after the study.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.I am willing to follow strict birth control measures or abstain from sex during and 5 months after the study.I have an autoimmune disease treated with strong medication in the last 2 years.I do not have serious heart issues like recent heart attacks or uncontrolled irregular heartbeats.I cannot swallow pills or have a condition that affects my stomach or intestines badly.I do not have any known allergies or severe side effects to the medications planned for my treatment.I have an active lymphoma in my brain or spinal cord.I have not had major surgery in the last 3 weeks.I have hepatitis B but it's under control with medication.I agree to use contraception and not donate sperm for 7 months after my last nivolumab dose.My cancer can be measured or seen on a PET scan.I am not on strong immune system suppressing drugs, except for low-dose or topical steroids.My cancer is at stage II-IV according to the Ann Arbor classification.My CLL has transformed into a more aggressive form.I have an active infection needing IV treatment or an uncontrolled infection.I was diagnosed with hepatitis C in the last 6 months.I am using effective birth control or am not of childbearing potential.My condition is early-stage primary mediastinal B-cell lymphoma or a type that's between DLBCL and Hodgkin’s.You have known allergies or bad reactions to any of the study drugs.I've had chemotherapy for lymphoma, but only used steroids or rituximab for mild cases.I have HIV with a low CD4 count or a high viral load.I can take care of myself and am up and about more than half of my waking hours.I have had another type of cancer that might interfere with this study.I have an active tuberculosis infection.My platelet count is at least 75,000 without recent transfusions.
- Group 1: Treatment (nivolumab, DA-REPOCH)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Nivolumab has received FDA approval, correct?
"While there is some data suggesting that Nivolumab is safe, it only received a score of 2 because this is a Phase 2 trial and thus there is no efficacy data to support its use."
How many people are included in the research project?
"This trial is not currently admitting patients. The listing for this clinical study was first posted on 1/2/2019 and last updated on 8/18/2022. However, there are 2415 trials for Nivolumab and 1895 studies for lymphoma that are enrolling patients at this time."
Are we looking for participants in this clinical trial at the moment?
"According to the clinicaltrials.gov listing, this research is not presently looking for participants. This study was originally published on 2nd January 2019 and updated on 18th August 2020. Even though this specific trial has completed recruitment, there are 4310 other studies that are still enrolling patients."
What other similar tests has Nivolumab undergone?
"As of now, 2415 Nivolumab trials are ongoing with 459 in Phase 3. The majority are based near Bethesda, Maryland; however, 98471 locations worldwide are running these sorts of tests."
What are the main health conditions that Nivolumab is effective against?
"Nivolumab is a medication typically given to patients with prostate cancer, however it has also shown efficacy in the treatment of squamous cell carcinoma, pheochromocytomas, and ulcerative colitis."
Share this study with friends
Copy Link
Messenger